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In the context of worldwide increasing antimicrobial resistance, good antimicrobial
prescribing in more needed than ever; unfortunately, information available to
clinicians often are insufficient to rely on. Biomarkers might provide help for
decision-making and improve antibiotic management. The purpose of this expert
panel review was to examine currently available literature on the potential role of
biomarkers to improve antimicrobial prescribing, by answering three questions: 1)
Which are the biomarkers available for this purpose?; 2) What is their potential role
in the initiation of antibiotic therapy?; and 3) What is their role in the decision to
stop antibiotic therapy? To answer these questions, studies reviewed were limited to
recent clinical studies (<15 years), involving a substantial number of patients (>50)
and restricted to controlled trials and meta-analyses for answering questions 2 and
3. With regard to the first question concerning routinely available biomarkers, which
might be useful for antibiotic management of acute infections, these are currently
limited to C-reactive protein (CRP) and procalcitonin (PCT). Other promising
biomarkers that may prove useful in the near future but need to undergo more
extensive clinical testing include sTREM-1, suPAR, ProADM, and Presepsin. New
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